Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Living Well with Scleroderma

Lara C. Pullen, PhD  |  Issue: March 2019  |  March 19, 2019

American College of Rheumatology

American College of Rheumatology

CHICAGO—Can non-drug interventions improve the lives of patients with scleroderma? Janet L. Poole, PhD, OTR/L, professor and director of the Occupational Therapy Graduate Program of the School of Medicine, University of New Mexico, Albuquerque, addressed this question when she presented the ARHP Distinguished Lecture at the 2018 ACR/ARHP Annual Meeting. She discussed the challenges faced by people with scleroderma as they manage their daily activities and summarized the evidence for non-pharmacological interventions for symptom management to improve the quality of life for these patients.

Disease Overview

Scleroderma, also known as systemic sclerosis, is a rare connective tissue disease that results in skin thickening, vascular insufficiency and fibrosis of internal organs. Approximately 60,000–100,000 people in the U.S. have the systemic form of scleroderma, a multi-system disease that includes organ involvement. People with scleroderma can develop painful calcium deposits under the skin on the fingers and over some larger joints, and they may have difficulty with swallowing due to problems moving food through the esophagus, Dr. Poole explained.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

About 95% of people with scleroderma have Raynaud’s phenomenon and may develop digital ulcers as a result of vascular problems. Contractures can develop in the finger joints; people may lose the ability to fully straighten the middle joints of the fingers. This type of joint contracture translates to an increased likelihood the patient will bump the joint, forming ulcers that may be slow to heal due to ischemia and repeated irritation. Ulcers and joint contractures can result in decreased motion, dexterity and function in the hand. Because use of the hands is necessary for most activities of daily living, these impairments can have a significant negative effect on quality of life.

Scleroderma can cause a change in facial appearance as well, Dr. Poole stated. The skin on the face can become tight and, in some people, spidery blood vessels can appear on the face. Tight facial skin and fibrosis of the tendons can lead to decreased mouth opening. That, in turn, can make oral and dental care more difficult.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Earlier diagnosis and more effective medical and pharmacological treatment have meant people are living longer with scleroderma and experience more disability in their work, family and social lives. Between five and 10 years following diagnosis, approximately one-third of patients are work disabled, and by 20 years post-diagnosis, more than half of patients are work disabled. However, as the disease progresses, Dr. Poole explained, many patients learn to adapt and secure support.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsSystemic Sclerosis Tagged with:2018 ACR/ARHP Annual Meetingnon-pharmaceutical therapies

Related Articles

    The 2022 ARP President’s & Merit Awards

    November 6, 2022

    During ACR Convergence 2022 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Oksana Shufrych TKTK / Shutterstock.com

    Heated Gloves May Improve Hand Function in Diffuse Systemic Sclerosis

    October 16, 2017

    Systemic sclerosis (SSc), a subtype of scleroderma, is a rare, complex autoimmune disease characterized by widespread vasculopathy of the small arteries and fibroblast dysfunction.1,2 It has been described as a fibrosing micro­vascular disease, because vascular injury precedes and leads to tissue fibrosis.3 The resulting Raynaud’s phenomenon, pain, skin thickening and tightening, and multi-organ involvement have…

    New ARP President Janet Poole, PhD, OTR/L, FAOTA, Plans to Build Membership & Address Workforce Shortages

    November 6, 2019

    Dr. Poole’s cited priorities include building an interprofessional membership team through developing resources and promoting rheumatology to health professionals in many disciplines.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences